These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

172 related items for PubMed ID: 15385809

  • 1. Efficacy and safety of basiliximab with a tacrolimus-based regimen in liver transplant recipients.
    Marino IR, Doria C, Scott VL, Foglieni CS, Lauro A, Piazza T, Cintorino D, Gruttadauria S.
    Transplantation; 2004 Sep 27; 78(6):886-91. PubMed ID: 15385809
    [Abstract] [Full Text] [Related]

  • 2. Basiliximab in a triple-drug regimen with tacrolimus and steroids in liver transplantation.
    Gruttadauria S, Vasta F, Mandalà L, Cintorino D, Piazza T, Spada M, Verzaro R, Gridelli B.
    Transplant Proc; 2005 Sep 27; 37(6):2611-3. PubMed ID: 16182762
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. The role of basiliximab induction therapy in adult-to-adult living-related transplantation and deceased donor liver transplantation: a comparative retrospective analysis of a single-center series.
    Viganò J, Gruttadauria S, Mandalà L, Petridis I, Cintorino D, Li Petri S, Varotti G, Minervini M, Volpes R, Biondo D, Vizzini G, Marsh WJ, Marcos A, Gridelli B.
    Transplant Proc; 2008 Sep 27; 40(6):1953-5. PubMed ID: 18675099
    [Abstract] [Full Text] [Related]

  • 5. Anti-IL2 induction in liver transplantation with 93% rejection-free patient and graft survival at 18 months.
    Ramirez CB, Doria C, di Francesco F, Iaria M, Kang Y, Marino IR.
    J Surg Res; 2007 Apr 27; 138(2):198-204. PubMed ID: 17292404
    [Abstract] [Full Text] [Related]

  • 6. Basiliximab induction in adult liver transplant recipients with 93% rejection-free patient and graft survival at 24 months.
    Ramirez CB, Doria C, di Francesco F, Iaria M, Kang Y, Marino IR.
    Transplant Proc; 2006 Dec 27; 38(10):3633-5. PubMed ID: 17175352
    [Abstract] [Full Text] [Related]

  • 7. The renal-sparing efficacy of basiliximab in adult living donor liver transplantation.
    Lin CC, Chuang FR, Lee CH, Wang CC, Chen YS, Liu YW, Jawan B, Chen CL.
    Liver Transpl; 2005 Oct 27; 11(10):1258-64. PubMed ID: 16184544
    [Abstract] [Full Text] [Related]

  • 8. Comparative study of the cellular pharmacodynamics of tacrolimus in renal transplant recipients treated with and without basiliximab.
    Sugiyama K, Isogai K, Horisawa S, Toyama A, Satoh H, Saito K, Nakagawa Y, Tasaki M, Takahashi K, Hirano T.
    Cell Transplant; 2012 Oct 27; 21(2-3):565-70. PubMed ID: 22793066
    [Abstract] [Full Text] [Related]

  • 9. Immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with azathioprine-containing triple therapy in liver transplant recipients.
    Calmus Y, Scheele JR, Gonzalez-Pinto I, Jaurrieta EJ, Klar E, Pageaux GP, Scudamore CH, Cuervas-Mons V, Metselaar HJ, Prestele H, Girault D.
    Liver Transpl; 2002 Feb 27; 8(2):123-31. PubMed ID: 11862588
    [Abstract] [Full Text] [Related]

  • 10. Role of basiliximab in the prevention of acute cellular rejection in adult to adult living-related liver transplantation: a single center experience.
    Gruttadauria S, Mandalà L, Biondo D, Spampinato M, Lamonaca V, Volpes R, Vizzini G, Marsh J, Marcos A, Gridelli B.
    Biologics; 2007 Mar 27; 1(1):69-73. PubMed ID: 19707350
    [Abstract] [Full Text] [Related]

  • 11. Basiliximab versus antithymocyte globulin for prevention of acute renal allograft rejection.
    Sollinger H, Kaplan B, Pescovitz MD, Philosophe B, Roza A, Brayman K, Somberg K.
    Transplantation; 2001 Dec 27; 72(12):1915-9. PubMed ID: 11773888
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Usefulness of Tacrolimus without Basiliximab in Well-Matched Living-Donor Renal Transplant Recipients in Korea.
    Baek CH, Kim JH, Yu H, Shin E, Cho H, Kim H, Yang WS, Han DJ, Park SK.
    Exp Clin Transplant; 2016 Aug 27; 14(4):389-93. PubMed ID: 27228054
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Twenty-four hour steroid avoidance immunosuppressive regimen in liver transplant recipients.
    Ju WQ, Guo ZY, Ling X, He XS, Wu LW, Tai Q, Hu AB, Han M, Zhu XF.
    Exp Clin Transplant; 2012 Jun 27; 10(3):258-62. PubMed ID: 22631063
    [Abstract] [Full Text] [Related]

  • 17. Prevention of acute allograft rejection in nonhuman primate lung transplant recipients: induction with chimeric anti-interleukin-2 receptor monoclonal antibody improves the tolerability and potentiates the immunosuppressive activity of a regimen using low doses of both microemulsion cyclosporine and 40-O-(2-hydroxyethyl)-rapamycin.
    Hausen B, Gummert J, Berry GJ, Christians U, Serkova N, Ikonen T, Hook L, Legay F, Schuler W, Schreier MH, Morris RE.
    Transplantation; 2000 Feb 27; 69(4):488-96. PubMed ID: 10708100
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. One-year results of basiliximab induction and tacrolimus associated with sequential steroid and MMF treatment in pediatric kidney transplant recipient.
    Montini G, Murer L, Ghio L, Pietrobon B, Ginevri F, Ferraresso M, Cardillo M, Scalamogna M, Perfumo F, Edefonti A, Zanon GF, Zacchello G.
    Transpl Int; 2005 Jan 27; 18(1):36-42. PubMed ID: 15612981
    [Abstract] [Full Text] [Related]

  • 20. Basiliximab (Simulect) for the treatment of steroid-resistant rejection in pediatric liver transpland recipients: a preliminary experience.
    Aw MM, Taylor RM, Verma A, Parke A, Baker AJ, Hadzic D, Muiesan P, Rela M, Heaton ND, Mieli-Vergani G, Dhawan A.
    Transplantation; 2003 Mar 27; 75(6):796-9. PubMed ID: 12660504
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.